ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Belzutifan (Welireg)

New indication (Carcinoma, Renal Cell, von Hippel-Lindau Disease). The wording is on the EMA page.

Conditional
CHMP opinion 12 Nov 2026 · Merck Sharp & Dohme B.V.
EU · EU licence (European Commission)

Belzutifan (Welireg)

Renal cell carcinoma (RCC) Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies. von Hippel-Lindau (VHL) disease-associated tumours Welireg is… Show the full indication

Renal cell carcinoma (RCC) Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies. von Hippel-Lindau (VHL) disease-associated tumours Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

Conditional
CHMP opinion 12 Dec 2024 → EU licence 12 Feb 2025 · Merck Sharp & Dohme B.V.

Research

Oncology · Lancet · 2026-08-12

In 747 patients with advanced clear-cell renal cell carcinoma progressing after anti-PD-1/PD-L1 therapy, belzutifan-lenvatinib vs cabozantinib improved median PFS (14·8 vs 10·7 months; HR 0·70) at interim analysis; overall survival was not significantly different (HR 0·85).

RCTn = 747
Motzer et al. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.